問卷

TPIDB > Search Result

Search Result

篩選

List

874Cases

2025-04-01 - 2032-12-31

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
18Sites

Recruiting18Sites

2023-06-01 - 2027-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
19Sites

Not yet recruiting1Sites

Recruiting18Sites

2023-06-01 - 2025-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2023-07-01 - 2027-11-30

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting8Sites

2023-07-01 - 2026-09-30

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-07-01 - 2026-06-30

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-07-03 - 2026-12-31

Phase II/III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-08-01 - 2027-04-01

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2023-08-01 - 2027-04-30

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites